DejanJuricMD

Breast Cancer, Clinical Pharmacology

Director, Termeer Center for Targeted Therapies, Massachusetts General Hospital

Dr. Juric is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
55 Fruit St
Boston, MA 02114
Phone+1 617-726-6500

Fax+1 617-724-1079

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2009 - 2012
Massachusetts General HospitalResidency, Internal Medicine, 2007 - 2009
University of Zagreb Faculty of MedicineClass of 2001

PubMed

Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors.
Jason J Luke, David J Pinato, Dejan Juric, Patricia LoRusso, Peter J Hosein
Journal for Immunotherapy of Cancer. 2025-02-20
TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.
Rachel O Abelman, Bogang Wu, Haley Barnes, Arielle Medford, Bryanna Norden
Clinical Cancer Research. 2025-01-02
1 citations
Financial toxicity in early-phase cancer clinical trial participants.
Sienna M Durbin, Debra Lundquist, Andrea Pelletier, Laura A Petrillo, Viola Bame
Cancer. 2025-01-01

Lectures

Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-)...
2019 ASCO Annual Meeting - 6/1/2019

Well-Designed Phase Ia and Ib Trials Point the Way to New Treatment OptionsMarch 5th, 2025
Evaluating Inavolisib vs Alpelisib plus Fulvestrant for Hormone Receptor-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast CancerSeptember 24th, 2024
Remembering JoséMarch 30th, 2021
Join now to see all